Yamazaki, K.
Doi, T.
Ikeda, M.
Okusaka, T.
Schueler, A.
Watanabe, M.
Ohtsu, A.
Funding for this research was provided by:
Merck KGaA
Article History
Received: 17 July 2019
Accepted: 7 August 2019
First Online: 3 September 2019
Compliance with ethical standards
:
: KY has received lecture fees from Merck Serono. TD has received research funding from Taiho, Novartis, Merck Serono, Merck Sharpe and Dohme, Boehringer Ingelheim, Pfizer, Lilly, Sumitomo Dainippon, Kyowa Hakko Kirin, Daiichi Sankyo, Bristol-Myers Sqiibb, Abbvie and Eisai, and has consulted/advised Kyowa Hakko Kirin, Merck Sharpe and Dohme, Amgen, Sumitomo Dainippon, Taiho, Takeda, Abbvie, Novartis and Bayer. MI has received research grants from Bayer Yakuhin, Kyowa Hakko Kirin, Eli Lilly Japan, Eisai, Chugai Pharmaceutical, and Bristol-Myers Sqiibb, and a speaker honorarium from Bayer Yakuhin and Eisai. MI is a member of advisory boards of Bayer Yakuhin and Eisai. AS is an employee of Merck Healthcare KGaA, Darmstadt, Germany. MW is an employee of Merck Serono Co Ltd, Tokyo, Japan. TO and AO declare that they have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.